These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

689 related articles for article (PubMed ID: 31941015)

  • 1. Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences.
    Hong SH; Choi KM
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31941015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcopenic obesity.
    Polyzos SA; Margioris AN
    Hormones (Athens); 2018 Sep; 17(3):321-331. PubMed ID: 30014320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The implications of sarcopenia and sarcopenic obesity on cardiometabolic disease.
    Kim TN; Choi KM
    J Cell Biochem; 2015 Jul; 116(7):1171-8. PubMed ID: 25545054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments.
    Wang M; Tan Y; Shi Y; Wang X; Liao Z; Wei P
    Front Endocrinol (Lausanne); 2020; 11():568. PubMed ID: 32982969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
    Asrih M; Jornayvaz FR
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatty liver as a consequence and cause of insulin resistance: lessons from type 2 diabetic liver.
    Takamura T; Misu H; Ota T; Kaneko S
    Endocr J; 2012; 59(9):745-63. PubMed ID: 22893453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarcopenic obesity in fatty liver.
    Merli M; Lattanzi B; Aprile F
    Curr Opin Clin Nutr Metab Care; 2019 May; 22(3):185-190. PubMed ID: 30893090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Vicious Cycle of Myostatin Signaling in Sarcopenic Obesity: Myostatin Role in Skeletal Muscle Growth, Insulin Signaling and Implications for Clinical Trials.
    Consitt LA; Clark BC
    J Frailty Aging; 2018; 7(1):21-27. PubMed ID: 29412438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin Resistance, Obesity, and Lipotoxicity.
    Yazıcı D; Demir SÇ; Sezer H
    Adv Exp Med Biol; 2024; 1460():391-430. PubMed ID: 39287860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative Review.
    Armandi A; Rosso C; Caviglia GP; Ribaldone DG; Bugianesi E
    Front Endocrinol (Lausanne); 2021; 12():716533. PubMed ID: 34858322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential mechanisms of muscle mitochondrial dysfunction in aging and obesity and cellular consequences.
    Chanséaume E; Morio B
    Int J Mol Sci; 2009 Jan; 10(1):306-324. PubMed ID: 19333447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Sarcopenia on Non-Alcoholic Fatty Liver Disease.
    Iwaki M; Kobayashi T; Nogami A; Saito S; Nakajima A; Yoneda M
    Nutrients; 2023 Feb; 15(4):. PubMed ID: 36839249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body composition and its association with cardiometabolic risk factors in the elderly: a focus on sarcopenic obesity.
    Chung JY; Kang HT; Lee DC; Lee HR; Lee YJ
    Arch Gerontol Geriatr; 2013; 56(1):270-8. PubMed ID: 23079031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations of Mitochondrial Function and Insulin Sensitivity in Human Obesity and Diabetes Mellitus.
    Koliaki C; Roden M
    Annu Rev Nutr; 2016 Jul; 36():337-67. PubMed ID: 27146012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin resistance and sarcopenia: mechanistic links between common co-morbidities.
    Cleasby ME; Jamieson PM; Atherton PJ
    J Endocrinol; 2016 May; 229(2):R67-81. PubMed ID: 26931135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exercise Therapy for People With Sarcopenic Obesity: Myokines and Adipokines as Effective Actors.
    Alizadeh Pahlavani H
    Front Endocrinol (Lausanne); 2022; 13():811751. PubMed ID: 35250869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarcopenic obesity or obese sarcopenia: A cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis.
    Kalinkovich A; Livshits G
    Ageing Res Rev; 2017 May; 35():200-221. PubMed ID: 27702700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Ageing- and Diet-Related Swine Models of Sarcopenia and Sarcopenic Obesity.
    Garcia-Contreras C; Vazquez-Gomez M; Torres-Rovira L; Gonzalez J; Porrini E; Gonzalez-Colaço M; Isabel B; Astiz S; Gonzalez-Bulnes A
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29534532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resveratrol prevents sarcopenic obesity by reversing mitochondrial dysfunction and oxidative stress via the PKA/LKB1/AMPK pathway.
    Huang Y; Zhu X; Chen K; Lang H; Zhang Y; Hou P; Ran L; Zhou M; Zheng J; Yi L; Mi M; Zhang Q
    Aging (Albany NY); 2019 Apr; 11(8):2217-2240. PubMed ID: 30988232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of weight loss and exercise in correcting skeletal muscle mitochondrial abnormalities in obesity, diabetes and aging.
    Toledo FG; Goodpaster BH
    Mol Cell Endocrinol; 2013 Oct; 379(1-2):30-4. PubMed ID: 23792186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.